213 related articles for article (PubMed ID: 32474034)
21. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
22. SARS CoV-2 infection among patients using immunomodulatory therapies.
Winthrop KL; Brunton AE; Beekmann S; Polgreen P; Baddley J; Saag KG; Calabrese C; Calabrese L; Robinson PC; Wallace ZS; Curtis JR;
Ann Rheum Dis; 2021 Feb; 80(2):269-271. PubMed ID: 32759259
[No Abstract] [Full Text] [Related]
23. Treatment, management, and monitoring of established rheumatoid arthritis.
Bingham CO; Miner MM
J Fam Pract; 2007 Oct; 56(10 Suppl Rapid):S1-7; quiz S8. PubMed ID: 17949607
[No Abstract] [Full Text] [Related]
24. Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure.
Brusasco C; Corradi F; Di Domenico A; Raggi F; Timossi G; Santori G; Brusasco V; ;
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33033151
[TBL] [Abstract][Full Text] [Related]
25. What is the true incidence of COVID-19 in patients with rheumatic diseases?
Favalli EG; Ingegnoli F; Cimaz R; Caporali R
Ann Rheum Dis; 2021 Feb; 80(2):e18. PubMed ID: 32321723
[No Abstract] [Full Text] [Related]
26. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
Jiménez-Brítez G; Ruiz P; Soler X
Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713
[No Abstract] [Full Text] [Related]
27. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.
Song J; Kang S; Choi SW; Seo KW; Lee S; So MW; Lim DH
Rheumatol Int; 2020 Jun; 40(6):991-995. PubMed ID: 32314010
[TBL] [Abstract][Full Text] [Related]
28. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
[TBL] [Abstract][Full Text] [Related]
29. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic.
Schulze-Koops H; Specker C; Iking-Konert C; Holle J; Moosig F; Krueger K
Ann Rheum Dis; 2020 Jun; 79(6):840-842. PubMed ID: 32345619
[No Abstract] [Full Text] [Related]
30. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.
D'Silva KM; Serling-Boyd N; Hsu TY; Sparks JA; Wallace ZS
Ann Rheum Dis; 2021 Jun; 80(6):817-819. PubMed ID: 33436385
[No Abstract] [Full Text] [Related]
31. Coexistence of ankylosing spondylitis and rheumatoid arthritis in a female patient.
Baksay B; Dér A; Szekanecz Z; Szántó S; Kovács A
Clin Rheumatol; 2011 Aug; 30(8):1119-22. PubMed ID: 21505766
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study.
Salvarani C; Bajocchi G; Mancuso P; Galli E; Muratore F; Boiardi L; Catanoso M; Pipitone N; Cassone G; Girolimetto N; Croci S; Cimino L; Gradellini F; Beltrami M; Di Lernia V; Dolci G; Massari M; Marata AM; Costantini M; Giorgi Rossi P
Ann Rheum Dis; 2020 Jul; 79(7):986-988. PubMed ID: 32467245
[No Abstract] [Full Text] [Related]
33. Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers.
Shimada H; Kameda T; Kanenishi K; Miyatake N; Nakashima S; Wakiya R; Kato M; Miyagi T; Mansour MMF; Hata T; Kadowaki N; Dobashi H
Clin Rheumatol; 2019 May; 38(5):1453-1458. PubMed ID: 30729372
[TBL] [Abstract][Full Text] [Related]
34. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
Misra DP; Agarwal V; Gasparyan AY; Zimba O
Clin Rheumatol; 2020 Jul; 39(7):2055-2062. PubMed ID: 32277367
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies.
Elemam NM; Maghazachi AA; Hannawi S
Curr Med Res Opin; 2021 Jun; 37(6):929-938. PubMed ID: 33754931
[TBL] [Abstract][Full Text] [Related]
36. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
Liao TL; Chen YM; Liu HJ; Chen DY
BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
[TBL] [Abstract][Full Text] [Related]
37. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
Bjornsson AH; Grondal G; Kristjansson M; Jonsdottir T; Love TJ; Gudbjornsson B;
Ann Rheum Dis; 2021 May; 80(5):671-672. PubMed ID: 33402343
[No Abstract] [Full Text] [Related]
38. Patients with rheumatoid arthritis exposed to COVID-19: A family cluster report.
Cai S; Sun W; Zhong J; Dong L
Mod Rheumatol; 2021 Mar; 31(2):514-517. PubMed ID: 32930030
[No Abstract] [Full Text] [Related]
39. [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Malek SA; Bouchti IE
Pan Afr Med J; 2020; 35(Suppl 2):134. PubMed ID: 33193949
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry.
Kihara M; Sugihara T; Asano J; Sato M; Kaneko H; Muraoka S; Ohshima S; Nanki T
Clin Rheumatol; 2022 Dec; 41(12):3661-3673. PubMed ID: 35974224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
